Aaron Sandoski

Aaron Sandoski is a seasoned medical technology venture capitalist with over 15 years of early-stage investing experience. He co-founded Norwich Ventures in 2004, an early-stage medtech venture capital firm that backs entrepreneurs solving significant healthcare problems through innovative medical technologies. In 2020, he expanded his investment activities by joining as a founding Managing Partner of the Medtech Convergence Fund (MCF), a $90 million early-stage fund managed under SV Health Investors in Boston.

Aaron's education reflects his multidisciplinary approach to healthcare investing. He graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics, combining rigorous scientific training with business acumen. He later earned his MBA from Harvard Business School, where he also served as a teaching fellow and won the prestigious Allyn Young Teaching Prize for his excellence in instruction.

Before founding Norwich Ventures, Aaron worked for DEKA Research & Development, the renowned engineering organization led by inventor Dean Kamen (creator of the Segway and numerous medical devices). At DEKA, he helped develop partnerships and formulate business plans for emerging technologies, gaining invaluable experience in translating cutting-edge engineering into viable commercial products. Prior to DEKA, Aaron began his professional career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to rural hospital systems. He also gained hands-on startup experience, helping launch a subsidiary of Express Scripts and working at a venture-backed payments company.

Beyond his investing activities, Aaron is a published author and thought leader. He co-authored "How the Wise Decide: The Lessons of 21 Extraordinary Leaders" with Bryn Zeckhauser (published by Crown Business), a book on best practices in making tough decisions based on interviews with 21 business leaders. The book has been translated into 11 foreign languages and is widely used in business education. Aaron has served as a guest lecturer on medical technology, innovation, and finance at Harvard University and Stanford University, and he is an active board member of MassMEDIC, Massachusetts' leading medtech trade association.

On a personal level, Aaron enjoys family adventures and has a passion for classic cars. He is based in the Boston area with his family.

Aaron Sandoski and his firms, Norwich Ventures and the Medtech Convergence Fund, focus exclusively on early-stage medical technology companies that address significant healthcare challenges through innovative technology platforms. Norwich Ventures is explicitly agnostic about the field of medicine, having supported companies across diverse areas including electrophysiology, genomics, women's health, diagnostics, and surgical devices.

The Medtech Convergence Fund represents an evolution in Aaron's investment approach, focusing on the convergence of advanced materials science, component miniaturization, sensors and software, telecommunications, and new delivery models to create disruptive solutions for significant and costly health challenges. The fund's investment philosophy emphasizes three major shifts in healthcare delivery: from intervention to prevention, invasive to non-invasive procedures, and hospital-based care to home-based care. MCF particularly prioritizes technologies that expand patient access via telehealth or utilize monitoring technologies to manage chronic disease, reflecting the broader trend toward remote patient monitoring and decentralized healthcare.

Aaron looks for entrepreneurs who combine deep technical expertise with a clear understanding of clinical problems and market dynamics. He values founders who can navigate the complex regulatory environment of medical devices while building scalable commercial models. His dual background in chemistry and economics, combined with his McKinsey training and DEKA experience, enables him to evaluate both the scientific merit and business viability of medtech innovations.

Norwich Ventures and MCF typically invest at the seed and early stages, providing foundational capital to help companies develop prototypes, conduct early clinical studies, and achieve key regulatory milestones. Aaron takes an active role in portfolio companies, often serving on boards and leveraging his extensive network in the medtech ecosystem to facilitate partnerships, business development, and follow-on financing.